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Background: The antiviral therapy of chronic hepatitis B virus (HBV) infection pursues the dual goals, virological
response (undetectable serum HBV DNA) and hepatitis B e antigen (HBeAg) serological response (serum HBeAg
loss/seroconversion). It is relatively difficult, however, to realize the serological response, especially for nucleotide/
nucleoside analogs. Furin, a proprotein convertase, is involved in HBeAg maturation. The suppression of furin using
inhibitors accordingly reduces HBeAg secretion, but possibly enhances HBV replication. For these reasons, the
strategy based on the combination of nucleoside analog entecavir (ETV) and furin inhibitors to inhibit HBV
replication and HBeAg secretion simultaneously were studied here.
Methods: The suppression of furin was performed using inhibitors decanoyl-RVKR-chloromethylketone (CMK) and
hexa-D-arginine (D6R) or the expression of furin inhibitory prosegment. The influence of furin suppression on HBV
replication and the effect of CMK combined with nucleoside analog entecavir (ETV) on HBV replication and HBeAg
secretion was investigated in HepG2.2.15 cells. HBeAg level in media was detected using enzyme-linked immunosorbent
assay. Intracellular viral antigens and HBV DNA were detected using Western and Southern blotting analyses,
respectively.
Results: CMK, D6R and the expression of inhibitory prosegment all significantly reduced HBeAg secretion, but
only CMK enhance HBV replication. Concordantly, only CMK post-transcriptionally accumulated cytosolic HBV
replication-essential hepatitis B core antigen (HBcAg). The HBcAg-accumulating effect of CMK was further
found to be resulted from its redundant inhibitory effect on the trypsin-like activity of cellular proteasomes
that are responsible for HBcAg degradation. Moreover, the viral replication-enhancing effect of CMK was abrogated by
ETV and ETV combined with CMK reduced HBV replication and HBeAg secretion simultaneously.
Conclusion: The suppression of furin itself does not enhance HBV replication. Nucleotide/nucleoside analogs
combined with furin inhibitors may be a potential easy way to realize the dual goals of the antiviral therapy for chronic
hepatitis B in the future.
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Hepatitis B virus (HBV) infections annually cause 1 mil-
lion of deaths worldwide [1,2]. Antiviral therapy is an
important way to improve the prognoses of these victims.
Hepatitis B surface antigen (HBsAg) loss or seroconver-
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unless otherwise stated.therapy. However, hepatitis B e antigen (HBeAg) serocon-
version (HBeAg serological response) and undetectable
HBV DNA (virological response) are common goals to be
pursued in clinical practice since on-treatment HBsAg
loss or seroconversion is difficult to realize, but it would
automatically occurs in patients from years to decades
after HBeAg seroconversion. HBeAg is a well-known
immune-toleragen [3]. Its persistence is an independent
risk factor for hepatocellular carcinoma and is associated
with a lower survival rate among cirrhotic patients [4,5].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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portant in establishing a benign prognosis [6,7]. Compared
with virological response only, virological response plus
HBeAg serological response have a low relapse relate
while off treatment of current antiviral therapy [7].
Though those patients with HBeAg seroconversion
(HBeAg-negative chronic hepatitis B) due to infection
of HBeAg-defective variants also have poor prognoses,
the significance of HBeAg to HBV infection is not
minimized since these variants rarely cause a de novo
chronic infection [8], implying that HBeAg loss may be
helpful for termination of chronic HBV infection. There-
fore, early antiviral intervention in HBeAg-positive chronic
hepatitis B may benefit all patients. In addition, early thera-
peutic intervention is helpful to reduce the risks for long-
term complications while on-treatment [9,10]. However,
current antiviral options including recombinant interferon
and nucleoside/nucleoside analogs cannot rapidly and eco-
nomically realize the dual goals of the antiviral therapy. For
example, nucleoside analog entecavir (ETV) blocks HBV
replication rapidly, but induce HBeAg seroconversion un-
predictably. For these reasons, ETV combined with some
direct HBeAg secretion-inhibitory measures seems a strat-
egy to improve the current antiviral therapy of chronic
hepatitis B.
HBeAg is encoded by the C open reading frame of the
viral genome. This frame also encodes viral core protein
(also called hepatitis B core antigen, HBcAg, 21 kDa).
Compared with HBcAg, the initial peptide of HBeAg has
an extra precore region consisting of a 19-amino acid
signal peptide that directs the nascent peptide into the
secretory pathway. After the signal peptide is removed
in the lumen of the endoplasmic reticulum, the HBeAg
precursor is generated and transported to the trans-
Golgi network. The HBeAg precursor (pre-HBe, 22 kDa)
is further cleaved by proprotein convertase furin in the
arginine-rich domains of the C-terminus to generate the
mature HBeAg (17 ~ 20 kDa) [11,12]. Furin belongs to
the subtilisin/kexin-like serine protease family. It is re-
sponsible for the majority of proprotein processing, and
thus not only plays critical roles in normal cell growth
and differentiation, but is also involved in many disease
states, such as Alzheimer’s disease, tumoriogenesis, and
infections [13]. Our previous studies have shown that
persistent HBV infection prefers to occur in patients car-
rying highly active genotypes of furin and furin inhibi-
tors, decanoyl-RVKR-chloromethylketone (CMK) and
hexa-D-arginine (D6R), reduce HBeAg secretion without
interfering with cellular protein secretion in HepG2.2.15
cells [14,15]. In addition, HBeAg reduction resulted from
furin inhibition leads to increase in cell surface expression
of immune-promoting pre-HBe [15], which is different
from HBeAg reduction or loss caused by infection of
HBeAg-defective variants, suggesting that furin inhibitionmay have less risk to let the infection develop into poorly
prognostic HBeAg-negative chronic hepatitis B. Though it
is not a traditional antiviral strategy, the direct inhibition
of HBeAg secretion mediated by the immune-regulation
effects may be helpful for the treatment of chronic HBV
infection. Thus, the suppression of furin may be a promis-
ing candidate way to improve HBeAg serological response
to ETV by inhibiting HBeAg secretion directly.
CMK and D6R are small synthetic furin inhibitors that
are suitable for the clinical purpose. CMK is a referential
furin inhibitor in many laboratories. It is more effective
than D6R in reduction of HBeAg secretion [15]. How-
ever, CMK and a mutation (T147A) adjacent to a puta-
tive furin recognition site (151RRGR154) in HBcAg of
HBeAg-defective variant (carrying the precore stop mu-
tation, G1896A) have been found to enhance HBV repli-
cation [15,16]. In the current study, we wonder whether
the suppression of furin by other measures enhances
HBV replication and the combination with ETV inhibits
HBV replication and HBeAg secretion simultaneously.
As results, furin suppressed by measures other than
CMK did not enhance HBV replication. CMK was found
to enhance HBV replication by inhibiting the trypsin-
like (TL) activity of proteasomes. The viral replication-
enhancing effect of CMK was abrogated by ETV. ETV
combined with CMK could simultaneously reduce HBV
replication and HBeAg secretion. These findings high-
light a novel approach to improve the antiviral therapy
for chronic HBV infections.
Results
Furin suppressed by measures other than CMK does not
enhance HBV replication
A strain of HBeAg-defective variant (G1896A) harboring
additional mutations, T147A and V149I, adjacent to a
putative furin recognition site in the C-terminus of
HBcAg, has higher replication efficiency than the con-
ventional variant. CMK can enhance the replication of
the latter variant to the level of the former variant
[16]. Here, the influence of CMK on the replication of
wild-type HBV was firstly tested. When HepG2.2.15, a
wild-type HBV-producing cell line, was used in this
study, CMK was found to increase the level of intracel-
lular core-associated HBV DNA in a dose-dependent
manner (Figure 1A). CMK reduces HBsAg secretion at
high concentrations (15), perhaps by interfering with
furin proteolyzation of HBV large surface antigen pre-S1
that simultaneously affect HBV virion release, implying
that CMK at high concentrations may also interfere with
HBV virion release; however, the enhancements based on
the increased level of intracellular core-associated HBV
DNA were not resulted from the limitation to virion
release since the virion level in media did not signifi-
cantly decrease (Figure 1B), and were neither related
Figure 1 The influences of furin suppression on HBV replication. HepG2.2.15 cells were regularly cultivated and treated with and without
furin inhibitors (20 μmol/L CMK and 100 μmol/L D6R unless marked particularly), or transfected with empty pIRES2-EGFP vector (pIRES2) or furin
inhibitory prosegment-expressing recombinant vector (pfurin-PS). Intracellular core-associated HBV DNA was detected using Southern blot
analysis. Relaxed circular (RC) HBV DNA was the HBV genome, and single-stranded linear (SS) HBV DNA was the replication intermediates.
Virion-related HBV DNA in culture medium was quantified using real-time fluorescent PCR. HBeAg was detected using enzyme-linked immunosorbent
assay. Furin inhibitory prosegment was detected using Western blot analysis. A: CMK increased intracellular core-associated HBV DNA. B: CMK increased
or unaffected the level of HBV virions in the media. *P <0.05. C: D6R and the expression of furin inhibitory prosegment inhibited HBeAg
secretion. *P < 0.05 and **P < 0.01. D: D6R and the expression of furin inhibitory prosegment did not enhance HBV replication.
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down-regulation using small interfering RNA has not
been found to enhance HBV replication [16], we fur-
ther tested whether HBV replication is enhanced by
D6R and the expression of furin inhibitory prosegment
that has been successfully used to inhibit furin activity
[17]. As results, they both significantly reduced HBeAg
secretion; however, they did not influence HBV repli-
cation and virion release (Figure 1C and D). The ex-
pression of furin inhibitory prosegment was successful
(Figure 1C, top right corner).
CMK accumulates cytosolic HBcAg and pre-HBe
The fact that only CMK enhances HBV replication sug-
gests that CMK may enhance HBV replication by furin-
unrelated mechanisms. CMK has been found to accu-
mulate intracellular HBcAg in the cells transfected with
HBeAg-defective variants of HBV [16], and the level of
intracellular HBcAg usually correlates the level of HBV
replication [18,19], suggest that HBcAg accumulation
may be responsible for HBV replication enhancement.
In this study, the effect of CMK was investigated in
HBeAg-competent HepG2.2.15 cells. HBcAg in this set-
ting would cross-react with pre-HBe and HBeAg duringWestern blot analysis. Since the critical processes of
HBV replication, such as capsid assembly, pregenomic
RNA encapsidation and reverse transcription, occur in
cytosol, and HBeAg matures in non-cytosol (endoplas-
mic reticulum and trans-Golgi network) of hepatocytes,
this study was performed after the cytosolic and non-
cytosolic proteins were separately extracted as reported
[20]. As results, CMK was found to accumulate HBcAg
in cytosol and to restrain the HBeAg maturation evi-
denced by pre-HBe increase and HBeAg decrease in
non-cytosol (Figure 2A), supporting it is the cytosolic
accumulation of HBcAg that correlates with HBV repli-
cation enhancement. This notion was further supported
by the findings that D6R and the expression of furin in-
hibitory prosegment without HBV replication-enhancing
capacity did not accumulate cytosolic HBcAg (Figure 2B).
CMK blocked the degradation of cytosolic HBcAg and
pre-HBe
Besides cytosolic HBcAg, pre-HBe in both cytosol and
non-cytosol was accumulated by CMK (Figure 2A). Our
previous study has shown that pre-HBe accumulated by
furin inhibition is subsequently expressed on cell surface
rather than retro-translocated into cytosol [15]. Thus,
Figure 2 The influences of furin suppression on the cellular
expression of HBcAg and pre-HBe. HepG2.2.15 cells were regularly
cultivated and treated with or without furin inhibitors (20 μmol/L
CMK and 100 μmol/L D6R), or transfected with empty pIRES2-EGFP
vector (pIRES2) or furin inhibitory prosegment-expressing recombinant
vector (pfurin-PS). HBcAg (HBc, 21 kDa), pre-HBe (22 kDa) and HBeAg
(HBe, 17 ~ 20 kDa) in cytosol and non-cytosol were detected
using Western blot analysis. A: CMK inhibited HBeAg maturation
in non-cytosol and accumulated HBcAg and pre-HBe in cytosol.
B: D6R and the expression of furin inhibitory prosegment did not
accumulate cytosolic HBcAg and pre-HBe. C: The turnover rates
of both HBcAg and pre-HBe in cytosol were down-regulated by
CMK when new protein synthesis was halted by cycloheximide (CHX).
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and pre-HBe in primary structure, suggest that CMK pos-
sibly interfere with the degradation of these antigens in
cytosol. Indeed, the turnover rates of both HBcAg and
pre-HBe were decreased by CMK when cellular protein
biosynthesis was blocked by cycloheximide (Figure 2C).
CMK selectively inhibited the TL activity of proteasomes
Furin and other proprotein convertases exist in the non-
cytosolic fraction (e.g., the trans-Golgi network), sup-
porting that these proteases are absolutely irrelevant to
cytosolic HBcAg and pre-HBe degradations. In fact,
cytosolic HBcAg and pre-HBe have been reported to
be degraded in cellular ubiquitin-proteasome system
[19-21]. However, the accumulation of truncated HBcAg
by proteasome inhibitors [21] suggests that cytosolic
HBcAg and pre-HBe are partially proteolyzed by some
cellular proteases prior to proteasomal degradation.
Cellular HBcAg existing as dimers in virion, nucleo-
capsids or capsids is usually resistant to proteases ex-
cept for the protease-sensitive hinge (E145-D153, R150)
between the capsid assembly-competent and pregenomic
RNA encapsidation-competent domains of HBcAg [22].
Since that hinge is sensitive to trypsin and both furin and
trypsin belong to the serine protease superfamily, the in-
hibitory effect of CMK on trypsin was studied in vitro.
When recombinant HBcAg (156 amino acids) with a 6 ×
his-tag, 6 amino acids adjacent to R150, in the C-terminus
was digested by trypsin, a truncated HBcAg of 16 kDa was
generated, and CMK strongly blocked the digestion
process (Figure 3A). The truncated HBcAg lacked of 6 ×
his-tag and theoretically had 150 amino acid residues
based on its molecular weight, suggesting that the cleav-
age indeed occurred in the hinge.
Since cytosolic HBcAg and pre-HBe are inaccessible to
trypsin in hepatocytes, their degradations could correlate
with some cellular TL proteases, for example, hepsin, a
small cellular TL protease. This protease primarily func-
tions on the surface of hepatocytes, but some cytoplasmic
form reportedly exists [23]. Unexpectedly, recombinant
HBcAg was not digested by the cytosolic extract from
HepG2 cells (parental cells of HepG2.2.15) (Figure 3B),
suggesting that HBcAg and pre-HBe were directly de-
graded in the ubiquitin-proteasome system and that CMK
could be capable of inhibiting the TL activity of protea-
somes. Indeed, CMK selectively inhibited the TL activity
without the changes in the protein level of proteasome
subunits (Figure 3C and D), and even the selective inhib-
ition was observed when the inhibitor was added to cell
lysates (Figure 3E). On the other hand, D6R and the ex-
pression of furin inhibitory prosegment without HBcAg-
accumulating capacity did not significantly affected the TL
activity of proteasomes (Figure 3 F). Together, CMK
directly and selectively inhibited the TL activity of
Figure 3 The mechanism for CMK to accumulate cytosolic HBcAg and pre-HBe. Recombinant HBcAg with 6 × his-tag in the C-terminus
(rHBc) was digested by trypsin, and the products were demonstrated using Western blot analysis with either a polyclonal antibody to HBcAg
(anti-core) or monoclonal antibody to 6 × his-tag (anti-his-tag). Proteasome activities were demonstrated using a commercial system, and results
were expressed as times of the protease activities of the treatment groups over those of the control group. Columns and vertical bars represented
the mean ± SD of three separate experiments. *P < 0.05 and **P < 0.01. A: CMK inhibited trypsin to digest rHBc into truncated fragments of
16 kDa (F/16kD). The truncated rHBc lost the 6 × his-tag. B: rHBc was not digested by the cytosolic extract from HepG2 cells. C: CMK selectively
inhibited the TL activity when cells were treated for 2 hours. D: CMK did not affect the α and β subunits of proteasomes (α + β/subunits) in
protein levels when compared with the housekeeping gene (β-actin). E: CMK selectively inhibited the TL activity when cell lysates were
treated for 2 hours. F: D6R (100 μmol/L) and the prosegment expression did not affect the activities of proteasomes.
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and HBV replication enhancement.
ETV abrogates the HBV replication-enhancing effect of
CMK
Although D6R and the expression of furin inhibitory
prosegment both successfully reduced HBeAg secretion,
D6R was less effective than CMK (Figure 1), perhaps
due to the poor permeability [24], and the expression of
the inhibitory prosegment depends on gene transfection
techniques that their widespread uses are hindered by
concerns over the safety in vivo. For these reasons, howto abrogate the HBV replication-enhancing effect of
CMK was further tested in this study. ETV is one of the
most effective nucleotide/nucleoside analogs that have
been extensively used [25,26]. Here, we found that ETV
not only completely abrogated the enhancing effect of
CMK, but also its HBV replication-inhibitory effect was
not significantly affected by CMK (Figure 4A).
ETV combined with CMK simultaneously reduces HBV
replication and HBeAg secretion
ETV was effective in inhibiting HBV replication in
HepG2.2.15 cells; however, it hardly affected HBeAg
Figure 4 Influences of ETV combined with CMK on the HBV
replication and HBeAg secretion. HepG2.2.15 cells were regularly
cultivated and treated with or without CMK (20 μmol/L) and/or ETV
(30 nmol/L). Intracellular core-associated HBV DNA was detected
using Southern blot analysis. Relaxed circular (RC) HBV DNA was the
HBV genome, and single-stranded linear (SS) HBV DNA was the
replication intermediates. Virion-related HBV DNA in culture
medium was quantified using real-time fluorescent PCR. HBeAg
and HBsAg were detected using enzyme-linked immunosorbent
assay. A: ETV abrogated the HBV replication-enhancing effect of
CMK. B: ETV combined with CMK reduced HBV replication and
HBeAg secretion simultaneously. **P < 0.01.
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with its satisfactory virological response and dissatis-
factory HBeAg serological response in clinical practice
[27,28]. On the other hand, CMK significantly inhib-
ited HBeAg secretion, but enhanced HBV replication
(Figure 1). In order to realize the dual goals of the
antiviral therapy, the potential antiviral effects of ETV
combined with CMK were further tested in HepG2.2.15
cells. The results clearly showed that ETV combined with
CMK inhibited virion release and HBeAg secretion simul-
taneously though their inhibition efficiencies were com-
parable with those of mono-treatments (Figure 4B).
Together with reducing intracellular core-associated
HBV DNA (Figure 4A), the combination strategy in-
deed realized the simultaneous reduction of HBV rep-
lication and HBeAg secretion.
Discussion
The current antiviral therapy of chronic HBV infection
pursues the dual goals, virological and HBeAg sero-
logical responses; however, the later seems difficult to
realize. Our previous study has shown that furin activity
correlated with the outcome of HBV infection and furin
inhibitors can significantly reduce HBeAg secretion with-
out interference with the secretion of cellular secretory
proteins [14,15]. Unfortunately, CMK, the more effective
inhibitor, enhances HBV replication [15,16]. In this study,
the suppressions of furin using D6R and the expression of
furin inhibitory prosegment were not found to enhance
HBV replication and HBV replication enhanced by CMK
was found to correlate with its redundant inhibitory effect
on the TL activity of proteasomes, suggesting that furininhibition itself does not promote HBV replication. Fur-
thermore, ETV combined with CMK was found to reduce
HBV replication and HBeAg secretion simultaneously,
which are concordant with the virological and serological
responses pursued with a vengeance in antiviral practice.
HBV replication enhancements of CMK and the muta-
tion (T147A) are accompanied by intracellular HBcAg
accumulation [16], and HBcAg is structural protein with
its intracellular level usually correlating with viral repli-
cation level [18,19]. The findings support that HBcAg
accumulation accounts for the HBV replication enhance-
ment of CMK and the mutation. Because HBcAg and
pre-HBe have identical furin-sensitive arginine-rich do-
mains, the above findings also suggest that furin may
proteolyze HBcAg. Therefore, it is reasonable to concern
the unfavorable HBV replication-enhancing effect of
furin inhibition. Fortunately, the suppression of furin
itself was not found to enhance HBV replication in this
study, which was evidenced by the facts: (i) D6R incuba-
tion and furin inhibitory prosegment expression inhibited
HBeAg secretion, but did not enhance HBV replication;
(ii) CMK enhanced HBV replication, but which was via
a redundant inhibitory effect on the TL activity of
proteasomes.
As furin is involved in the maturation of membrane
fusion proteins and pro-toxins of bacteria and viruses,
furin inhibition using inhibitors is viewed as a potential
therapeutic strategy for anthrax, influenza A and Ebola
virus infection [13,29,30].The significance of HBeAg to
persistent HBV infection [8], the correlations of furin ac-
tivity with the outcomes of HBV infection [14], and the
lack of influences on cell secretory function [15], and
HBV replication in this study suggest that the suppres-
sion of furin is also a promising novel strategy for the
antiviral therapy of HBV infection in the future. Due to
the lack of natural inhibitors, furin inhibitors used at
present all are man-made compound. Although many re-
searchers make effort to develop new inhibitors [24,29,30],
no medicinal inhibitors are available at present. CMK and
D6R are small synthetic inhibitors suitable for clinical pur-
pose. CMK has used as a reference furin inhibitor in cell-
based tests and inhibits HBeAg secretion in HepG2.2.15
cells [15,16]; however, it enhances HBV replication, which
is in conflict with the goal of antiviral therapy. Compared
with CMK, D6R is more sensitive in cell-free test system
or targeting furin on the cell surface, but less effective in
inhibiting HBeAg secretion in cell-based test system
[15,24,31,32], perhaps due to its poor permeability [24].
For these reasons, the development of new furin inhibitors is
imperative in the future. Our findings, including those in this
study, are helpful to determine the target and orientation of
the development process, paying attention to the specificity,
especially not to affect the TL activity of proteasomes, and
the permeability to reach the trans-Golgi network.
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furin has a long way to go, to make use of current inhib-
itors is a reasonable option. In this study, ETV was
found to abrogate the HBV replication enhancement of
CMK, and ETV combined with CMK inhibited HBV
replication and HBeAg secretion simultaneously in
HepG2.2.15 cells. Although no synergistic effect was ob-
served, these results imply that it would be possible to
realize the virological and serological responses of the
antiviral therapy rapidly and economically. However,
much more studies should be carried out to clarify the
effectiveness and safety of the combination strategy
in vivo. Theoretically, ETV abrogates HBV replication
enhancement but HBcAg accumulation of CMK. The
remained HBcAg accumulation may have a chance to in-
duce the aggravation of the inflammation and cell injury
by increasing the presentation of HBcAg epitopes. It is
less likely, however, to lead to fatal liver dysfunction
since the generation of these epitopes depends on cellu-
lar proteasomes that have been inhibited by CMK. Of
course, new effective inhibitors without effects on
HBcAg accumulation would be the first choice of the
combination therapy in the future. Besides HBeAg, CMK
and furin knockdown with small interfering RNA lead to
the reduction of HBsAg [33]. Our previous study further
demonstrates that CMK only at higher concentration
(100 μmol/L) suppresses the biosynthesis of HBsAg [15].
In this study, HBsAg-reducing effect of CMK was not
found, perhaps due to the lower concentration (20 μmol/L)
employed. Nonetheless, it is important to pursue the in-
hibitory effect on HBsAg in novel inhibitor development
or therapy regimen establishment in the future since
HBsAg seroconversion is the perfect end-point of anti-
viral therapy for chronic HBV infection.
Conclusions
Furin-inhibiting measures other than CMK did not en-
hance HBV replication and CMK enhanced HBV replica-
tion by affecting the TL activity of proteasomes, suggesting
that furin inhibition itself does not lead to HBV replication.
ETV could completely abrogate the HBV replication en-
hancement of CMK. Moreover, ETV combined with CMK
reduced HBV replication and HBeAg secretion simultan-
eously in HepG2.2.15 cells, which implies that nucleotide/
nucleoside analogs combined with some furin inhibitors
may be an easy way to realize the dual goals of antiviral
therapy. Nonetheless, more studies on the effectiveness
and safety of the combination strategy in vivo are war-
ranted in the future.
Methods
Plasmid construct
Furin inhibitory prosegment-expressing vector (pfurin-PS)
was constructed using plasmid pIRES2-EGFP (Clontech,Palo Alto, CA). The sequence of the inhibitory proseg-
ment was designed from those coding 109 amino acids of
the N-terminus of furin (gene ID: 5045). The sequence of
the construct had been confirmed using DNA sequencing.
Cell culture, transfection, and protease inhibitor
treatments
HepG2.2.15 cells were regularly grown in Dulbecco’s modi-
fied Eagle’s medium, supplemented with 10% (vol/vol) fetal
calf serum and 380 μg/mL of geneticin if necessary. Transi-
ent transfection was performed using FuGENE HD trans-
fection reagent (Roche Applied Science, Indianapolis, IN).
Cells were treated with 10 ~ 50 μmol/L CMK (EMD
Biosciences, La Jolla, CA, USA) or 100 μmol/L D6R
(EMD Biosciences) with or without 30 nmol/L ETV
(Sigma-Aldrich Corporation, St. Louis, MO, USA) for
48 hours in a growth arrest medium containing 0.5%
(vol/vol) fetal calf serum after confluent growth. The
cells (107) were harvested to evaluate HBV replication
and viral antigen expression. To perform virion release
and cell viability assays, cells were further cultivated
using fresh medium for 12 hours. To evaluate the turn-
over rate of HBcAg, cells were treated with or without cy-
cloheximide, a protein synthesis inhibitor (Sigma-Aldrich
Corporation, St. Louis, MO, USA), and harvested in
12 hour intervals to a maximum of 48 hours.
Detections of core-associated HBV DNA
The isolation of supernatant and intracellular core parti-
cles was performed as reported [34]. Sampling was bal-
anced based on the protein level in cell lysate. Supernatant
core-associated HBV DNA was quantitatively analyzed
using commercial real-time fluorescent polymerase chain
reaction (PCR) kits (Daan Gene Inc., Guangzhou, China).
The intracellular core-associated HBV DNA was detected
used Southern blot analysis. The isolated DNA was sepa-
rated and transferred onto nylon membranes (Roche Ap-
plied Science, Indianapolis, IN, USA). After hybridized
with digoxigenin-labeled DNA probes, all membranes
were incubated with horseradish peroxidase-labeled anti-
digoxigenin antibody (Roche Applied Science), and de-
veloped with an enhanced chemiluminescence reagent
(Invitrogen Corporation, Shanghai, China).
Detections of intracellular viral antigens, furin inhibitory
prosegment and proteasome subunits
For the detections of proteasome subunits or intercellu-
lar HBeAg, pre-HBe and HBcAg, total cellular protein
or cytosolic and non-cytosolic cellular proteins were ex-
tracted as reported [20]. The total or sorted cellular pro-
teins were separated and transferred onto polyvinylidene
fluoride membranes (Millipore Corporation, Billerica,
MA, USA) using standard techniques. Immunoblot ana-
lysis was performed using polyclonal antibodies to HBcAg
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Span BioSciences Inc., Seattle, WA, USA) or the prote-
asome subunits (ab22673; Abcam, Cambridge, UK).
Protease digestion assay
The trypsin (Sigma-Aldrich Corporation) digestion of re-
combinant HBcAg, a fragment of 156 amino acids with
a 6 × histidine (his)-tag in the C-terminus (Millipore Cor-
poration), was performed as described elsewhere [22]. To
study the putative proteolysis of recombinant HBc by the
cytosolic proteases of cells, cytosolic extract was prepared
from 106 HepG2 cells by incubating for 3 minutes on ice
with 1 mL of a digitonin buffer (50 mmol/L Tris [pH 8],
150 mmol/L NaCl, and 22.5 μg/mL digitonin), and centri-
fuging at 1500 × g for 2 minutes at 4°C.
Proteasome activity assay
The TL, chymotrypsin-like, and caspase-like activities of
the proteasomes were measured using commercial cell-
based kits (Proteasome-GloTM, Promega, Madison, WI,
USA) as described previously [35]. Luminescence was
recorded using a luminometer (Promega).
Statistical analysis
The differences in virion release, HBeAg and HBsAg se-
cretions and proteasome activities were analyzed using the
Student’s t-test. A P < 0.05 was considered statistically sig-
nificant. All statistical analyses were conducted using SPSS
software (version 11; SPSS, Inc., Chicago, IL, USA).
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